-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 5, Lisheng Pharmaceutical issued an announcement stating that its subsidiary, Central Pharmaceuticals, had recently received the "Approval for Drug Supplement" (batch number: 2021B03871) for the 0.
Cefdinir dispersible tablets (0.
Pharyngitis, tonsillitis, acute bronchitis, pneumonia;
Otitis media, sinusitis;
Pyelonephritis, cystitis, gonococcal urethritis;
Annexitis, intrauterine infection, bartholinitis;
Secondary infections of mastitis, abscesses around the anus, trauma or surgical wounds;
Folliculitis, furuncle, boils, carbuncle, infectious impetigo, erysipelas, cellulitis, lymphangitis, paronychia, subcutaneous abscess, acne infection, chronic pyoderma;
Blepharitis, sty, meibomitis